Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Patent
1995-01-13
1997-11-04
Guzo, David
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
514 44, 536 231, 536 245, 4353201, C12Q 168, A61K 4800, C07H 2102, C07H 2104
Patent
active
056838735
ABSTRACT:
Modified external guide sequence (EGS) molecules that mediate cleavage of specific target RNAs have been constructed. The modified molecules are external guide sequence molecules for RNAse P which are designed to specifically bind to and promote RNAse P-mediated cleavage of target RNA molecules and to have enhanced nuclease resistance. Specific regions are modified to achieve enhanced stability while maintaining RNAse P activity. Modified external guide sequence molecules suitable for use in the treatment of hepatitis B viral infections have been constructed.
REFERENCES:
patent: 4868116 (1989-09-01), Morgan et al.
patent: 4980286 (1990-12-01), Morgan et al.
patent: 5168053 (1992-12-01), Altman et al.
patent: 5225347 (1993-07-01), Goldberg et al.
patent: 5334711 (1994-08-01), Sproat et al.
patent: 5525719 (1996-06-01), Srivastava et al.
Milligan et. al. J. of Medicinal Chemistry, Jul. 9, 1993, vol. 36 (14): 1923-1936.
Christoffersen and Marr, J. of Medicinal Chemistry, Jun. 9, 1995, vol 38 (12): 2023-2037.
Gaur, et al., Nucl. Acids Res. 21(1), 21-26 (Jan. 11, 1993).
Ma, et al., J. Cell. Biochem. Supp. 211, 5-26, (Jan. 1995).
Symons, Curr. Op. Struct. Biol. 4(3), 322-330 (Jun. 1, 1994).
Usman, et al., Nuc. Acids. Res. Symp. Ser. 31, 163-164 (Nov. 9, 1994)).
Agrawal et al., "Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus," Proc. Natl. Acad. Sci. USA, 85:7079-7083 (1988).
Altman, S., "RNA enzyme-directed gene therapy," Proc. Natl. Acad. Sci. USA 90:10898-10900 (1993).
Bartkiewicz et al., "Identification and characterization of an RNA molecule that copurifies with RNase P activity from HeLa cells," Genes Dev. 3:488-499 (1989).
Cech, T., "Self-Splicing Of Group I Introns," Annu. Rev. Biochem., 59:543-568, (1990).
Clarenc, J.P., et al., "Delivery of antisense oligonucleotides by poly(L-lysine) conjugation and liposome encapsulation," Anti-Cancer Drug Design, 8:81-94 (1993).
Felgner, P.L. et al., "Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure," Proc. Natl. Acad. Sci. USA, 84:7413-7417 (1987).
Felgner, P.L., "Particulate systems and polymers for in vitro and in vivo delivery of polynucleotides," Advanced Drug Delivery Reviews, 5:163-187 (1990).
Felgner, P.L. et al., "Cationic liposome-mediated transfection," Nature, 337:387-388 (1989).
Forster, A.C. and Altman, "External Guide Sequences for an RNA Enzyme," S., Science, 249:783-786 (1990).
Grigoriev et al., "A Triple Helix-forming Oligonucleotide-Intercalator Conjugate Acts as a Transcriptional Repressor via Inhibition of NF kB Binding to Interleukin-2 Receptor .alpha.-Regulatory Sequence," J. Biol. Chem., 267:3389-3395 (1992).
Guerrier-Takada, C., et al., "The RNA Moiety of Ribonuclease P Is the Catalytic Subunit of the Enzyme," Cell, 35:849-857 (1983).
Heidenreich and Eckstein, "Hammerhead Ribozyme-mediated Cleavage of the Long Terminal Repeat RNA of Human Immunodeficiency Virus Type 1," J. Biol. Chem., 267:1904-1909 (1992).
Hoke et al., "Effects of phosphorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection," Nucleic Acids Res. 19:5743-5748 (1991).
Ikuta et al., "Synthesis and use of Synthetic Oligonucleotides," Ann. Rev. Biochem., 53:323-356 (1984).
P. Johnson and J.G. Lloyd-Jones. eds., Drug Delivery Systems (Chichester, England: Ellis Horwood Ltd., 1987).
Kim, et al., "Preparation of Multivesicular liposomes," Biochim. Biophys. Acta. 728:339-348 (1983).
Lee, et al., "Recognition of liposomes by cells: in vitro binding and endocytosis mediated by specific lipid headgroups and surface charge density," Biochim. Biophys. Acta., 1103:185-197 (1992).
Liu, D., et al., "Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM.sub.1 -containing liposomes," Biochim. Biophys. Acta, 1104:95-101 (1992).
Maher et al., "Inhibition of DNA Binding Proteins by Oligonucleotide-Directed Triple Helix Formation," Science, 245:725-730 (1989).
Milligan, et al., "Oligoribonucleotide synthesis using T7 RNA polymerase and synthetic DNA templates" Nucl Acids Res., 15:8783 (1987).
Mulligan, "The Basic Science of Gene Therapy," Science, 260:926-932 (1993).
Narang et al., "Chemical Synthesis of Deoxyoligonucleotides by the Modified Triester Method," Methods Enzymol., 65:610-620 (1980).
Offensperger et al., "In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides" EMBO J., 12:1257-1262 (1993).
Ogilvie et al., "Total chemical synthesis of a 77-nucleotide-long RNA sequence having methionine-acceptance activity," Proc. Natl. Acad. Sci. U.S.A., 85:5764-5768 (1988).
Orson et al., "Oligonucleotide inhibition of IL2R.alpha. mRNA transcription by promoter region collinear triplex formation in lymphocytes," Nucl. Acids Res., 19:3435-3441 (1991).
Paolella et al., "Nuclease resistant ribozymes with high catalytic activity" EMBO J., 11:1913-1919 (1992).
Pieken, et al., "Kinetic Characterization of Ribonuclease-Resistant 2'-Modified Hammerhead Ribozymes," Science, 253:314-317 (1991).
Pugh, 1990*.
Robinson, 1990*.
Rossi, J.J., et al., "Exploring the Use of Antisense, Enzymatic RNA Molecules (Ribozymes) as Therapeutic Agents" Antisense Res. Dev., 1:285-288 (1991).
Sarin et al., "Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates," Proc. Natl. Acad. Sci, USA, 85:7448-7794 (1989).
Scaringe et al., "Chemical synthesis of biologically active oligoribonucleotides using .beta.-cyanoethyl protected ribonucleoside phosphoramidites," Nucleic Acids Research, 18:5433-5441 (1990).
Seela, F. and Kaiser, K., "Oligodeoxyribonucleotides containing 1,3-propanediol as nucleoside substitute," Nucleic Acids Res., 15:3113-3129 (1987).
Shaw et al., "Modified deoxyoligonucleotides stable to exonuclease degradation in serum," Nucleic Acids Res. 19:747-750 (1991).
Symons R.H., "Small Catalytic RNAs," Annu. Rev. Biochem., 61:641-671 (1992).
Thierry, A.R. and Dritschilo, A., "Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity," Nucl. Acids Res., 20:5691-5698 (1992).
Wang, et al., "Highly Efficient DNA Delivery Mediated by pH-Sensitive Immunoliposomes," Biochem., 28:9508-9514 (1989).
Yuan, Y. and Altman, S., "Selection of Guide Sequences That Direct Efficient Cleavage of mRNA by Human Ribonuclease P," Science, 263:1269-1273 (1994).
Yuan. Y., Hwayng, E.S. and Altman, S., "Targeted cleavage of mRNA by human RNase P," Proc. Natl. Acad. Sci., USA, 89:8006-8010 (1992).
Zhu et al., "Systemic Gene Expression After Intravenous DNA Delivery into Adult Mice," Science, 261:209-211 (1993).
George Shaji T.
Goldberg Allan R.
Ma Michael
Pace Umberto
Werner Martina
Guzo David
Innovir Laboratories, Inc.
Sandals William
LandOfFree
EGS-mediated inactivation of target RNA does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with EGS-mediated inactivation of target RNA, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and EGS-mediated inactivation of target RNA will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1832191